Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy

Fig. 4

Percentage cell death in ovarian cancer cells 7-days after azacitidine, carboplatin or combination azacitidine and carboplatin treatment in (A) all cell lines, (B) BRCA-wildtype cell lines, and (C) BRCA-mutant cell lines. Percentage cell death is represented as the mean ± SEM of triplicates of three independent experiments

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us